{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:40:30Z","timestamp":1793932830078,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ajo.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:08:05Z","timestamp":1675901285000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Static Perimetry in the Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A) Study: Assessment Through 2 Years"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9593-6412","authenticated-orcid":false,"given":"Jacque L.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-2467","authenticated-orcid":false,"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-7536","authenticated-orcid":false,"given":"Allison A.","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-2897","authenticated-orcid":false,"given":"David G.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-5375","authenticated-orcid":false,"given":"Janet K.","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-0329","authenticated-orcid":false,"given":"Todd A.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9737-054X","authenticated-orcid":false,"given":"Abigail T.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel B.","family":"Hoyng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6310-5748","authenticated-orcid":false,"given":"Hiroshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4943-6599","authenticated-orcid":false,"given":"Mark E.","family":"Pennesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-911X","authenticated-orcid":false,"given":"Katarina","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10097","key":"10.1016\/j.ajo.2023.02.002_bib0001","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ajo.2023.02.002_bib0002","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2023.02.002_bib0003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2023.02.002_bib0004","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1038\/mtna.2016.89","article-title":"Antisense oligonucleotide-based splice correction for USH2A-associated retinal degeneration caused by a frequent deep-intronic mutation","volume":"5","author":"Slijkerman","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"issue":"8","key":"10.1016\/j.ajo.2023.02.002_bib0005","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","article-title":"Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations","volume":"29","author":"Dulla","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2023.02.002_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.omtm.2019.11.016","article-title":"Genome editing in patient iPSCs corrects the most prevalent USH2A mutations and reveals intriguing mutant mRNA expression profiles","volume":"17","author":"Sanjurjo-Soriano","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.ajo.2023.02.002_bib0007","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaophthalmol.2020.6418","article-title":"Analysis of pathogenic variants correctable with CRISPR base editing among patients with recessive inherited retinal degeneration","volume":"139","author":"Fry","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2023.02.002_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/genes12060805","article-title":"Generation and genetic correction of USH2A c.2299delG mutation in patient-derived induced pluripotent stem cells","volume":"12","author":"Liu","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ajo.2023.02.002_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajo.2020.05.024","article-title":"Baseline visual field findings in the RUSH2A study: associated factors and correlation with other measures of disease severity","volume":"219","author":"Duncan","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2023.02.002_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.9.11.9","article-title":"The RUSH2A study: best-corrected visual acuity, full-field electroretinography amplitudes, and full-field stimulus thresholds at baseline","volume":"9","author":"Birch","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"10.1016\/j.ajo.2023.02.002_bib0011","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1002\/ajmg.a.62437","article-title":"Auditory and olfactory findings in patients with USH2A-related retinal degeneration\u2014findings at baseline from the rate of progression in USH2A-related retinal degeneration natural history study (RUSH2A)","volume":"185","author":"Iannaccone","year":"2021","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1016\/j.ajo.2023.02.002_bib0012","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1167\/iovs.08-2229","article-title":"Comparison of the new perimetric GATE strategy with conventional full-threshold and SITA standard strategies","volume":"50","author":"Schiefer","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2023.02.002_bib0013","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.4.2.14","article-title":"VFMA: topographic analysis of sensitivity data from full-field static perimetry","volume":"4","author":"Weleber","year":"2015","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"10.1016\/j.ajo.2023.02.002_bib0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11517-016-1485-x","article-title":"Comparison of nonparametric methods for static visual field interpolation","volume":"55","author":"Smith","year":"2017","journal-title":"Med Biol Eng Comput"},{"issue":"2","key":"10.1016\/j.ajo.2023.02.002_bib0015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2023.02.002_bib0016","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2023.02.002_bib0017","doi-asserted-by":"crossref","first-page":"N51","DOI":"10.1088\/0967-3334\/28\/8\/N02","article-title":"Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials","volume":"28","author":"Roman","year":"2007","journal-title":"Physiol Meas"},{"key":"10.1016\/j.ajo.2023.02.002_bib0018","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajo.2022.08.013","article-title":"Baseline microperimetry and OCT in the RUSH2A Study: structure\u2212function association and correlation with disease severity","volume":"244","author":"Lad","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2023.02.002_bib0019","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/jamaophthalmol.2016.0502","article-title":"Quantification of ellipsoid zone changes in retinitis pigmentosa using en face spectral domain\u2013optical coherence tomography","volume":"134","author":"Hariri","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2023.02.002_bib0020","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1214\/aos\/1176342503","article-title":"Robust regression: asymptotics, conjectures and Monte Carlo","volume":"1","author":"Huber","year":"1973","journal-title":"Ann Stat"},{"key":"10.1016\/j.ajo.2023.02.002_bib0021","series-title":"Paper presented at: SAS Conference Proceedings: SAS Users Group International","article-title":"Robust regression and outlier detection with the ROBUSTREG procedure","author":"Chen","year":"2002"},{"issue":"16","key":"10.1016\/j.ajo.2023.02.002_bib0022","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.visres.2011.06.009","article-title":"Assessment of linear-scale indices for perimetry in terms of progression in early glaucoma","volume":"51","author":"Gardiner","year":"2011","journal-title":"Vision Res"},{"issue":"4","key":"10.1016\/j.ajo.2023.02.002_bib0023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cne.902920402","article-title":"Human photoreceptor topography","volume":"292","author":"Curcio","year":"1990","journal-title":"J Comp Neurol"},{"issue":"9","key":"10.1016\/j.ajo.2023.02.002_bib0024","first-page":"3027","article-title":"Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations","volume":"43","author":"Berson","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2023.02.002_bib0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaophthalmol.2018.1171","article-title":"Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa: a randomized phase 2 multicenter placebo-controlled clinical trial","volume":"136","author":"Birch","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2023.02.002_bib0026","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.10.12.4","article-title":"Hierarchical censored bayesian analysis of visual field progression","volume":"10","author":"Montesano","year":"2021","journal-title":"Transl Vis Sci Technol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942300048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942300048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:53:30Z","timestamp":1757598810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942300048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":26,"alternative-id":["S000293942300048X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2023.02.002","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Static Perimetry in the Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A) Study: Assessment Through 2 Years","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}